| Antigen |
Clone |
| Rab11a |
STo 2F3 |
| Rab11a
|
Sto 7C10 |
| Rad17 |
Rad17 1C6/2 |
| Rad24 |
Polyclonal |
| Rad51 |
Rad51 3C10 |
| Rad51 |
Polyclonal SWE26 |
| Rad51B |
Rad51B 1E11/6 |
| Rad51B |
rad51b 1h3/13 |
| Rad51C |
Rad51C 2H11/6 |
| Rad51C |
polyclonal 3R68 |
| Rad51D |
Rad51D 5A8/4 |
| Rad51D |
Rad51D 5B3/6 |
| Rad52 |
Polyclonal FBE3 |
| Rad54 |
Rad54 4E3/1 |
| RAP1 |
RAP1 4C8/1 |
| RecA |
Polyclonal SWE8 |
| Retinoblastoma (Rb1) |
Rb1 |
| RNA pol II |
CTD 4H8 |
| RNA pol II (phospho) |
CTD 8A7 |
| Rough Endoplasmic Reticulum Component |
BU18 |
| RuvA |
RuvA 12C6 |
| RuvA |
Polyclonal SWE2 |
| RuvB |
RuvB 4G5/1 |
| RuvB |
Polyclonal SWE4 |
| RuvC |
RuvC 5G9/3 |
| RuvC |
RuvC 7F1/5 |
| RuvC |
Polyclonal SWE6 |
For further information about antibodies from CRT or to discuss sales or licensing options, please contact us at reagents@cancertechnology.com
Please note that CRT supplies to distributors only. However, we are happy to direct researchers to the appropriate commercial party to obtain antibodies within our portfolio. Click here to view disclaimer information. |
